University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of Chicago Medicine Comprehensive Cancer Center


Dr. Stadler on Sequencing Therapies in Prostate Cancer

September 22, 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

September 06, 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC

August 01, 2018

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer.

Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

March 01, 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21, 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

x